Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.

Scientific reports - 22 Aug 2017

Kong Xiaotian, Sun Huiyong, Pan Peichen, Li Dan, Zhu Feng, Chang Shan, Xu Lei, Li Youyong, Hou Tingjun

Abstract excerpt

Janus kinase 2 (JAK2) has been regarded as an essential target for the treatment of myeloproliferative neoplasms (MPNs). BBT594 and CHZ868, Type-II inhibitors of JAK2, illustrate satisfactory efficacy in preclinical MPNs and acute lymphoblastic leukemia (ALL) models. However, the L884P mutation of JAK2 abrogates the suppressive effects of BBT594 and CHZ868. In this study, conventional molecular dynamics (MD)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Site
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Entropy

Share to Janus Kinase 2

Share to Piperidines

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 28831147
DOI: 10.1038/s41598-017-09586-3
PMCID: PMC5567357

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.PMID 28831147Read ↗

Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.Semantic proximity Read ↗

Effects of the I682F mutation on JAK2's activity, structure and stability.Semantic proximity Read ↗

Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.Semantic proximity Read ↗

Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.Semantic proximity Read ↗

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.Semantic proximity Read ↗

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.Semantic proximity Read ↗

The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.Semantic proximity Read ↗

Impact of lymphoma-linked Asn11Tyr point mutation on the interaction between Bcl-2 and a BH3 mimetic: Insights from molecular dynamics simulation.Semantic proximity Read ↗

A novel approach to study multi-domain motions in JAK1's activation mechanism based on energy landscape.Semantic proximity Read ↗

Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.Semantic proximity Read ↗

Exploring conformation changes of Janus kinase 2 pseudokinase mediated by mutations through Gaussian accelerated molecular dynamics and principal component analysis.Semantic proximity Read ↗

Revealing imatinib-kinase specificity via analyzing changes in protein dynamics and computing molecular binding affinitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.